OBJECTIVE: To provide additional validity data for the Asthma Control TestTM (ACT) using a different criterion measure, setting, and population. STUDY DESIGN: Cross-sectional survey. METHODS: Questionnaires were completed at home by a random sample of 570 members of a large integrated healthcare organization who were 35 years or older with utilization suggestive of active asthma. The questionnaires included the ACT; another validated asthma control questionnaire (Asthma Therapy Assessment Questionnaire [ATAQ]), which was used as the criterion measure; a validated quality-of-life tool (Mini Asthma Quality of Life Questionnaire [Mini-AQLQ]); a validated symptom frequency scale (Asthma Outcomes Monitoring System); and information regarding demographics. RESULTS: The ACT score was statistically significantly correlated with findings on the ATAQ (P = -0.73), Mini-AQLQ (P = 0.77), and symptom frequency scale (P = -0.69). The optimal ACT cutoff for well-controlled asthma (ATAQ level, 0) was confirmed to be 20 or higher (sensitivity, 78.1%; specificity, 83.8%), and the optimal ACT cutoff for poorly controlled asthma (ATAQ level, 3-4) was confirmed to be 15 or lower (sensitivity, 90.4%; specificity, 80.9%). CONCLUSION: These data further support the validity of the ACT in the home setting among a random sample of patients with asthma.
OBJECTIVE: To provide additional validity data for the Asthma Control TestTM (ACT) using a different criterion measure, setting, and population. STUDY DESIGN: Cross-sectional survey. METHODS: Questionnaires were completed at home by a random sample of 570 members of a large integrated healthcare organization who were 35 years or older with utilization suggestive of active asthma. The questionnaires included the ACT; another validated asthma control questionnaire (Asthma Therapy Assessment Questionnaire [ATAQ]), which was used as the criterion measure; a validated quality-of-life tool (Mini Asthma Quality of Life Questionnaire [Mini-AQLQ]); a validated symptom frequency scale (Asthma Outcomes Monitoring System); and information regarding demographics. RESULTS: The ACT score was statistically significantly correlated with findings on the ATAQ (P = -0.73), Mini-AQLQ (P = 0.77), and symptom frequency scale (P = -0.69). The optimal ACT cutoff for well-controlled asthma (ATAQ level, 0) was confirmed to be 20 or higher (sensitivity, 78.1%; specificity, 83.8%), and the optimal ACT cutoff for poorly controlled asthma (ATAQ level, 3-4) was confirmed to be 15 or lower (sensitivity, 90.4%; specificity, 80.9%). CONCLUSION: These data further support the validity of the ACT in the home setting among a random sample of patients with asthma.
Authors: Michelle M Cloutier; Michael Schatz; Mario Castro; Noreen Clark; H William Kelly; Rita Mangione-Smith; James Sheller; Christine Sorkness; Stuart Stoloff; Peter Gergen Journal: J Allergy Clin Immunol Date: 2012-03 Impact factor: 10.793
Authors: Paul M Lehrer; Charles G Irvin; Shou-En Lu; Anthony Scardella; Beatrix Roehmheld-Hamm; Milisyaris Aviles-Velez; Jessica Graves; Evgeny G Vaschillo; Bronya Vaschillo; Flavia Hoyte; Harold Nelson; Frederick S Wamboldt Journal: Appl Psychophysiol Biofeedback Date: 2018-03
Authors: Rodrigo S Cavallazzi; Barbara J Polivka; Bryan L Beatty; Demetra E Antimisiaris; Rangaraj K Gopalraj; Rachel A Vickers-Smith; Rodney J Folz Journal: Respir Care Date: 2020-02-18 Impact factor: 2.258
Authors: Barbara J Polivka; Rodney Folz; John Myers; Russell Barnett; Demetra Antimisiaris; Anna Jorayeva; Bryan Beatty Journal: Res Nurs Health Date: 2018-08 Impact factor: 2.228
Authors: Yixin Shi; Ahramahzd V Tatavoosian; Anna S Aledia; Steven C George; Stanley P Galant Journal: Ann Allergy Asthma Immunol Date: 2012-07-04 Impact factor: 6.347
Authors: Kristin Palmsten; Michael Schatz; Priscilla H Chan; Diana L Johnson; Christina D Chambers Journal: J Allergy Clin Immunol Pract Date: 2016-01-05
Authors: Ann Chen Wu; Robert Davis; Kelan Tantisira; M Maya Dutta-Linn; Mia Hemmes; Scott T Weiss Journal: J Pharmacogenomics Pharmacoproteomics Date: 2011-04-04